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Abstract
Purpose Buprenorphine has low oral bioavailability. Regardless of sublingual administration, a notable part of buprenorphine is
exposed to extensive first-pass metabolism by the cytochrome P450 (CYP) 3A4. As drug interaction studies with buprenorphine
are limited, we wanted to investigate the effect of voriconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics and
pharmacodynamics of oral buprenorphine.
Methods Twelve healthy volunteers were given either placebo or voriconazole (orally, 400 mg twice on day 1 and
200 mg twice on days 2–5) for 5 days in a randomized, cross-over study. On day 5, they ingested 0.2 mg (3.6 mg
during placebo phase) oral buprenorphine. We measured plasma and urine concentrations of buprenorphine and
norbuprenorphine and monitored their pharmacological effects. Pharmacokinetic parameters were normalized for a
buprenorphine dose of 1.0 mg.
Results Voriconazole greatly increased the mean area under the plasma concentration–time curve (AUC0–18) of buprenorphine
(4.3-fold, P < 0.001), its peak concentration (Cmax) (3.9-fold), half-life (P < 0.05), and excretion into urine (Ae; P < 0.001).
Voriconazole also markedly enhanced the Cmax (P < 0.001), AUC0–18 (P < 0.001), and Ae (P < 0.05) of unconjugated
norbuprenorphine but decreased its renal clearance (P < 0.001). Mild dizziness and nausea occurred during both study phases.
Conclusions Voriconazole greatly increases exposure to oral buprenorphine, mainly by inhibiting intestinal and liver CYP3A4.
Effect on some transporters may explain elevated norbuprenorphine concentrations. Although oral buprenorphine is not com-
monly used, this interaction may become relevant in patients receiving sublingual buprenorphine together with voriconazole or
other CYP3A4 or transporter inhibitors.
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Introduction
Buprenorphine is a partial μ-opioid receptor agonist,
which antagonizes ĸ-opioid receptor and acts as an ago-
nist at the δ-opioid receptor and opioid receptor-like re-
ceptor [1, 2]. Buprenorphine is increasingly used for
treating acute and chronic pain. Analgesic doses range
from 0.3 to 0.6 mg when intravenous or intramuscular
dosing routes are used. Buprenorphine is also a good op-
tion for substitution therapy to treat opioid dependence
because of its pharmacokinetic and pharmacodynamic
properties. Buprenorphine produces long-lasting subjec-
tive and physiologic effects without significant respiratory
depression [3, 4]. Sublingual doses used in opioid substi-
tution therapy are much higher than those used in treat-
ment of chronic pain, but buprenorphine is considered to
be safe because of its ceiling effects [4].
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Buprenorphine has very low oral bioavailability be-
cause of its extensive first-pass metabolism [5, 6]. The
bioavai labi l i ty is higher, about 15–30%, when
buprenorphine is administered sublingually [7, 8]. The
mean time to maximum plasma concentration following
sublingual administration varies from 1 to 3 h [9–12].
After an oral and sublingual buprenorphine administra-
tion, extensive first-pass metabolism and large interindi-
vidual variability increase the susceptibility to drug inter-
actions. Furthermore, many opioids are substrates to
some transporter proteins, such as P-glycoprotein, which
can affect their absorption and systemic clearance
[13–15].
The main metabolic pathway (65%) of buprenorphine
is cytochrome P450 (CYP) 3A4/5-media ted N-
dealkylation of the drug, which yields an active metabo-
lite, norbuprenorphine. CYP2C8 and CYP2C9 have been
also shown to metabolize buprenorphine [16–19].
Buprenorphine and norbuprenorphine are conjugated to
their 3-glucuronides mainly by the UDP-glucuronosyl
transferases (UGT) 2B7 and 1A1, and 1A3 and 1A1, re-
spectively [5, 20, 21]. Previous study with 63Ni electron-
capture gas chromatographic assay evaluated the levels
buprenorphine and its metabolites in human urine and
feces [22], and approximately 10–30% of the dose was
excreted in urine, mainly as conjugated metabolites.
Similar results have been published, showing that 15%
of conjugated metabolites are excreted in urine [5], and
only small amounts of unconjugated parent drug or
norbuprenorphine are excreted into urine; most of the
dose is eliminated in the feces [5, 23].
The effect of strong CYP3A4 inhibitors on the phar-
macokinetics of buprenorphine is largely unknown, par-
ticularly after its oral ingestion. A previous study showed
that ketoconazole does not have clinically significant in-
teractions with transdermally delivered buprenorphine
[24]. Other interaction studies have been conducted with
patients receiving simultaneous buprenorphine substitu-
tion and antiretroviral therapy [25]. Voriconazole is fre-
quently used in immunosuppressed patients with
suspected aspergillosis. Voriconazole is a potent inhibitor
of CYP3A4, CYP2B6, CYP2C9, and CYP2C19 enzymes
[26–28]. Oral buprenorphine is not commonly used in
clinical settings, but very large doses of sublingual
buprenorphine from 16 to 32 mg are administered in sub-
stitution therapy [29, 30]. A considerable part of the sub-
lingual dose can be swallowed, making buprenorphine
susceptible to first-pass metabolism in the gut wall and
liver [7, 31]. Here, we wanted to study the pharmacoki-
netics of oral buprenorphine after its immediate
swallowing, with or without voriconazole, to evaluate




In view of our previous studies [12, 32], it was calculated that
ten subjects would be needed to detect a 30% difference in the
area under the plasma concentration–time curve (AUC0–∞) of
buprenorphine at a power of 80% and level of significance of
P < 0.05. To also consider potential dropouts, we recruited 12
healthy non-smoking volunteers (4 females and 8 men; age
range 18 to 29 years; body mass index from 20.5 to 27.8 kg/
m2). E-mail announcements, assigned to university students,
were used to recruit participants. A written informed consent
was obtained. The criteria for exclusion included concomitant
drug therapy, previous history of intolerance to any of the drugs
studied, past history of significant disease, alcoholism, drug
abuse or psychological or emotional problems, blood donation
within 4 weeks prior to study, and participation in any other
studies involving drug products within 1 month prior to this
study. Female participants were given instructions to use safe
non-hormonal contraception during the study because hormon-
al contraceptives were not allowed. Clinical examination and
routine laboratory tests were performed to evaluate participants’
physical health. Their medical history was also evaluated, and
all 12 participants were found to be in good physical health.
Urine toxicology and pregnancy tests were negative and ECGs
were in normal limits. The Finnish translation of the Abuse
Questions [33] was used to evaluate the risk of participants to
develop opioid abuse, and the risk was found to be low for
every participant. Volunteers were not allowed to consume cof-
fee, tea, and energy drinks or grapefruit juice during the study.
Study outline and drug administration
The study protocol was approved by the ethics committee of the
Hospital District of Southwest Finland and by the Finnish
National Agency for Medicines and was registered in the
EudraCT clinical trials register under code 2011-001939-23.
The clinical phase of the study was conducted in the research
facilities of the Department of Clinical Pharmacology and
TYKSLab, University of Turku and Turku University
Hospital, Finland. The volunteers ingested orally, in random-
ized order either voriconazole or placebo for 5 days. Dosing of
voriconazole (Vfend® 200 mg tablet; Pfizer, Sandwich, Great
Britain) was 400mg at 8.00 and 20.00 on day 1, 200mg at 8.00
and 20.00 on days 2–4, and 200 mg at 10.00 and 20.00 on day
5. The washout interval in this cross-over study was 4 weeks.
On the fifth day of pretreatment, all subjects ingested a single
dose of 0.2 mg (3.6 mg during placebo phase) of oral
buprenorphine (Temgesic® 0.2 tablet RB Pharmaceuticals
Limited, Slough, Great Britain) with 200 ml of water at 11.00
on empty stomach.
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Adherence with the voriconazole/placebo dosing schedule
was assessed using mobile phone text messages. After taking
each dose, the subjects sent a mobile phone text message to
one of the investigators. The investigator contacted the subject
if no text message was received within 15–20min after sched-
uled dosing time and reminded them to take the dose. The
volunteers fasted overnight (8 h) before the administration of
buprenorphine. Standardized meals were served 4 and 8 h
after buprenorphine ingestion.
Blood sampling and drug analysis
On the test days, a forearm vein was cannulated, and timed
blood samples (10 ml) for pharmacokinetic measurements
were collected into ethylenediaminetetraacetic acid-
containing tubes immediately before and 0.5, 1, 1.5, 2, 3, 4,
5, 6, 8, 10, 12, and 18 h after the ingestion of buprenorphine.
Plasma was separated within 30 min and stored at − 70 °C
until drug analysis. Urine was collected up to 18 h after
buprenorphine administration. Urine aliquots were stored at
− 70 °C until analysis.
The concentrations of buprenorphine and norbuprenorphine
in plasma and urine samples were analyzed with a validated
liquid chromatography tandem mass spectrometric method as
previously described [12]. The low limit of quantification
(LLQ) for plasma and urine buprenorphine was 0.02 ng/ml and
for norbuprenorphine 0.05 ng/ml. Concentrations below the
LLQ but clearly detectable were used as LLQ/2 in calculation
of the mean (SD) concentrations. The interday coefficients of
variation (CV%) were for buprenorphine 8.0% at 5.3 ng/ml,
8.7% at 0.53 ng/ml, and 6.1% at 0.053 ng/ml and for
norbuprenorphine 3.7% at 4.8 ng/ml, 8.7% at 0.48 ng/ml, and
11.9% at 0.048 ng/ml.
Plasma concentrations of voriconazole were determined
from the samples taken on day 5 before administration of
buprenorphine by using liquid chromatograph equipped with
Waters Symmetry C8 column (Waters) and UV detection at
255 nm wave length as described before [34]. Diazepam was
used as the internal standard. The LLQ for voriconazole was
10 ng/ml. The CVs for voriconazole were below 10% at rel-
evant plasma concentration range, i.e., 7.5% at 4000 ng/ml,
3.0% at 1100 ng/ml, and 5.5% at 110 ng/ml.
Pharmacokinetic measurements
The peak plasma concentrations (Cmax) and corresponding
time to Cmax (tmax) of buprenorphine and norbuprenorphine
were observed directly from the data. The areas under the
buprenorphine and norbuprenorphine plasma concentration–
time curves (AUC) from 0 to 18 h (AUC0–18) were calculated
by non-compartmental methods using WinNonlin pharmaco-
kinetics program (version 4.1; Pharsight, Mountain View,
CA). The terminal log-linear part of each concentration–time
curve was identified visually, and the elimination rate constant
(ke) was calculated from the logarithmically transformed data
using linear regression analysis. The t1/2 was calculated using
the equation t1/2 = ln2/ke. The cumulative amount of unconju-
gated buprenorphine and unconjugated norbuprenorphine ex-
creted into urine was calculated from 0 to 18 h (Ae), and the
renal clearance (Clrenal) using the equation = Ae/AUC0–18. All
pharmacokinetic parameters were normalized for a
buprenorphine dose of 1.0 mg.
Statistical analysis
The AUC0–18 of buprenorphine was the primary outcome var-
iable in the study, and all other pharmacokinetic and all phar-
macodynamic parameters were secondary variables.
Geometric mean ratios with 90% CIs were calculated for the
pharmacokinetic variables. Lack of interaction was assumed if
the 90% CI of the geometric mean ratios for pharmacokinetic
variables were within the acceptance limit of 0.8–1.25.
Pharmacokinetic variables and pharmacological effects were
compared with paired Student’s t test. The values for tmax were
compared by the use of Wilcoxon signed rank test. The statis-
tical significance level was P < 0.05. The Pearson product
moment correlation coefficient was used to investigate the
possible relationship between the ratios of the AUC0–18 of
buprenorphine during the treatment phase (voriconazole) to
the AUC0–18 of buprenorphine during the control phase, as
well as to the Ctrough of voriconazole before the administration
of buprenorphine. The associations of plasma buprenorphine
concentrations with psychomotor and analgesic effects were
also calculated using the Pearson’s product moment correla-
tion coefficient. The results are expressed as mean values and
variation in data set is expressed as standard deviation (SD). R
software (version 3.2.0) and ggplot2 (version 2.1.0) were ap-
plied for statistical analysis and graphical presentation.
Results
Voriconazole affected strongly on the pharmacokinetics of
orally administered buprenorphine and increased its effects
(Fig . 1; Supplementary Figs . 1 and 2; Table 1;
Supplementary Tables 1 and 2).
Buprenorphine
Compared to placebo phase, voriconazole increased the mean
AUC0–18 of oral buprenorphine 4.3-fold (90% CI 2.7, 6.7
P < 0.001) and its Cmax 3.9-fold (90% CI 2.6, 5.9;
P < 0.001) (Table 1; Supplementary Fig. 2). Voriconazole
had no significant effect on the tmax, but it slightly prolonged
the t1/2 of buprenorphine (P = 0.042). Voriconazole increased
the amount of unconjugated buprenorphine excreted in urine
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(P < 0.001; Supplementary Fig. 1) but had no significant ef-
fect on its Clrenal. The Ae of unchanged (unconjugated)
buprenorphine was less than 0.1% of the dose during 18 h
even during the voriconazole phase.
Norbuprenorphine
Voriconazole increased the mean AUC0–18 of norbuprenorphine
nearly 4-fold (90% CI 3.0, 5.3; P < 0.001) and its Cmax 3.3-fold
(90% CI 2.4, 4.4; P < 0.001) compared to placebo phase
(Table 1). The metabolite to the parent drug ratio (AUCm/
AUCp) was not changed by voriconazole. Voriconazole en-
hanced the Ae of unconjugated norbuprenorphine by only 1.5-
fold (P = 0.029), and accordingly, voriconazole significantly
(P < 0.001) reduced its Clrenal (Supplementary Fig. 2).
Voriconazole
Themean (SD) plasma concentration of voriconazole (Ctrough)
was 1022 (1509) ng/ml before the administration of
buprenorphine during the voriconazole phase, and the concen-
trations ranged from 170 to 5715 ng/ml.
Table 1 Pharmacokinetic
parameters of buprenorphine and
norbuprenorphine after oral
administration of 3.6 mg (placebo
phase) or 0.2 mg (voriconazole
phase) buprenorphine on the fifth
day of pretreatment with
voriconazole (400 mg twice on
day 1, 200 mg twice on days 2–5)
or placebo in 12 healthy subjects
Parameter Placebo Voriconazole P value Geometric mean ratio
(90% CI)
Buprenorphine
Cmax (ng/ml) 0.057 ± 0.031 0.22 ± 0.23 < 0.001 3.87 (2.55, 5.88)
tmax (h) 0.5 (0.5–18) 2 (0.5–10) 0.06 –
AUC0–18 (ng h/ml) 0.43 ± 0.26 2.1 ± 1.4 < 0.001 4.27 (2.71, 6.73)
t1/2 (h) 9.1 ± 2.4 14.5 ± 6.8 0.042 1.43 (1.08, 1.89)
Ae (μg) 0.10 ± 0.063 0.53 ± 0.29 < 0.001 6.76 (4.68, 8.83)
CLrenal (l/h) 0.31 ± 0.23 0.73 ± 1.3 0.206 0.51 (0.053, 4.89)
Norbuprenorphine
Cmax (ng/ml) 0.11 ± 0.025 0.28 ± 0.26 < 0.001 3.29 (2.44, 4.43)
tmax (h) 2 (0.5–12) 5 (0.5–8) 0.35 –
AUC0–18 (ng h/ml) 1.07 ± 0.58 4.0 ± 2.1 < 0.001 3.95 (2.97, 5.26)
t1/2 (h) 13.1 ± 9.06 17.8 ± 7.9 0.12 1.52 (0.98, 2.38)
AUCm/AUCp 3.0 ± 1.5 3.8 ± 5.8 0.78 0.92 (0.57, 1.51)
Ae (μg) 6.9 ± 3.3 11.6 ± 7.8 0.029 1.54 (1.20, 1.98)
CLrenal (L/h) 7.2 ± 2.7 2.9 ± 1.2 < 0.001 0.39 (0.29, 0.52)
Values are normalized for an oral dose of 1.0 mg. Data are shown as mean ± standard deviation (SD) and as the
geometric mean ratios with the 90% confidence interval (CI) in parenthesis—except for tmax, which is given as
median and range
CI confidence interval, Cmax peak plasma concentration, tmax concentration peak time, AUC0–18 area under curve
from 0 to 18 h, t1/2 elimination half-life, Ae amount excreted into urine within 18 h, CLrenal renal clearance
Fig. 1 Mean (SD) plasma concentrations of buprenorphine and
norbuprenorphine in 12 healthy subjects after 3.6 mg (placebo phase) or
0.2 mg (voriconazole phase) of oral buprenorphine on the fifth day of
pretreatment with placebo (empty circle) or voriconazole (filled circle)
400 mg twice on day 1 and 200mg twice on days 2–5. Concentrations are
shown both on an arithmetic and a semilogarithmic scale (inset). Values
are normalized for an oral dose of 1.0 mg
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Pharmacological effects and adverse effects
Buprenorphine caused moderate pharmacological effects
(Supplementary Table 1), but their relevant comparison be-
tween the study phases is not possible due to different
buprenorphine doses. The most common adverse effects were
mild dizziness and nausea (Supplementary Table 2). There
were no severe adverse effects, and tropisetron, naloxone, or
any other rescue medication was not needed.
Discussion
We investigated the effect of voriconazole on buprenorphine
pharmacokinetics when buprenorphine was swallowed imme-
diately after its oral administration. Although oral ingestion is
not commonly used in clinical practice with buprenorphine, a
considerable part of the sublingual buprenorphine dose is usu-
ally swallowed and therefore susceptible to first-pass metabo-
lism. Furthermore, in some deliberate overdoses, subjects can
swallow buprenorphine concomitantly with other drugs,
which could inhibit buprenorphine metabolism and increase
respiratory depression. Our major finding was that
voriconazole greatly increases the exposure to both parent
buprenorphine and its active metabolite, norbuprenorphine,
in some subjects even 6-fold. On average, voriconazole in-
creased the AUC of oral buprenorphine two to three times
more than what we observed in a previous study using sub-
lingual administration [12].
There are only few previous studies characterizing the in-
teractions between buprenorphine and drugs which affect its
pharmacokinetics. Most of these studies have focused on
high-dose sublingual buprenorphine substitution therapy.
Atazanavir alone and with ritonavir increased the AUC of
buprenorphine and norbuprenorphine nearly 2-fold and lead
to an increased sedative effect [25]. Darunavir–ritonavir or
fosamprenavir–ritonavir combinations did not cause signifi-
cant changes in plasma buprenorphine or norbuprenorphine
levels [35]. Boceprevir increased plasma buprenorphine con-
centrations slightly but decreased norbuprenorphine concen-
tration in plasma [36]. Similarly, lopinavir–ritonavir did not
affect buprenorphine pharmacokinetics but did increase the
clearance of norbuprenorphine [37].We showed, recently, that
voriconazole and posaconazole increase exposure to sublin-
gual buprenorphine [12]. Rifampicin decreased the exposure
to sublingual but not to intravenous buprenorphine [32].
These results seem to emphasize the significant role of
CYP3A-mediated first-pass metabolism of buprenorphine,
which sublingual administration only partially bypasses.
Themetabolic fate of buprenorphine is complicated, and all
its details are still not fully elucidated. Buprenorphine is ex-
tensively N-dealkylated to norbuprenorphine, mainly by
CYP3A4 [16, 17] and to some extent by CYP2C8 [18].
Also, minor CYP3A4- and CYP2C8-catalyzed buprenorphine
hydroxylation pathways have been identified [18, 19, 38].
Voriconazole is a potent (Ki values << 10 μM) reversible in-
hibitor of CYP2B6, CYP2C9, CYP2C19, and CYP3A en-
zymes [28]. The Ki of voriconazole as a reversible inhibitor
of the CYP3A4-dependent formation of norbuprenorphine
has been estimated to be 5.91 μM [38]. In the present study,
the average plasma trough concentrations of voriconazole
were around 3 μM, which suggests a marked inhibition po-
tential for CYP3A4 during the whole 12-h dosing interval.
The effects of voriconazole on parent buprenorphine can be
mainly explained by inhibition of CYP3A4 during the first-
pass and elimination phases. However, the substantial in-
creases in the AUC and Cmax of norbuprenorphine suggest
the presence of additional mechanisms because inhibition of
CYP3A4 should decrease the N-dealkyla t ion of
buprenorphine to norbuprenorphine.
Buprenorphine and norbuprenorphine are also
glucuronidated. UGT2B7 accounts for more than 40% of
buprenorphine glucuronidation, while norbuprenorphine
glucuronidation is predominantly mediated by UGT1A3
[21]. Buprenorphine and norbuprenorphine are excreted in
bile as their glucuronides, but hydrolysis to unconjugated
forms by colonic bacterial beta-glucuronidases allows their
reabsorption and enterohepatic circulation. Feces contain
buprenorphine and norbuprenorphine predominantly in un-
conjugated form; in urine, they are mainly in conjugated form
[5]. Effects of voriconazole and its metabolites on different
UGTs and glucuronidases are not known. However, according
to a semiphysiological population pharmacokinetic model,
voriconazole emerges as an UGT2B inhibitor in the gut and
liver [39].
Voriconazole reduced the Clrenal of norbuprenorphine but
not that of buprenorphine. Previously, voriconazole has been
shown to decrease the Clrenal of diclofenac [40]. Reduction of
Clrenal values can be explained by inhibition of membrane
transporters as norbuprenorphine, but not buprenorphine, is
a substrate of the efflux transporter P-glycoprotein [20].
Because the urinary excretion of (unconjugated)
norbuprenorphine was very small, reduction of its Clrenal can-
not alone explain its high plasma concentrations. However,
voriconazole (or its metabolites) may have affected trans-
porters also in extrarenal tissues, and these effects may have
influenced the tissue distribution of norbuprenorphine. P-
glycoprotein is a major determinant of norbuprenorphine
brain exposure [20], whereas buprenorphine as a lipophilic
compound rapidly penetrates cell membranes without trans-
porters. P-glycoprotein can be found in the intestinal wall,
blood–brain barrier and many other tissues [41]. Thus, inhibi-
tion of P-glycoprotein and/or other transporters could influ-
ence, e.g., enterohepatic circulation and tissue concentrations
of norbuprenorphine. Of note, norbuprenorphine does not
have a ceiling effect on respiratory depression, and respiratory
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toxicity of buprenorphine can result from the blockade of P-
glycoprotein-mediated efflux of norbuprenorphine at the
blood–brain barrier [42]. Further studies are needed on the
effect of drug interactions on norbuprenorphine tissue distri-
bution and buprenorphine toxicity, keeping in mind also
Bopioid toxicity epidemic^ [43].
In the present study, relevant comparison of pharmaco-
logical effects between the two phases was not possible
because of different buprenorphine doses. We used only
relatively small doses to minimize the risk of adverse
events in healthy volunteers. The dose during the placebo
phase (3.6 mg vs. 0.2 mg) was set higher, because we
assumed a low oral bioavailability after immediate inges-
tion of the tablet. On the contrary, we wanted to keep the
dose in the voriconazole phase smaller, because of the
possibility of strong inhibition of buprenorphine metabo-
lism. We based this assumption on the previous results
which have established that voriconazole, and other
CYP3A4 inhibitors can dramatically increase exposure
to drugs that are metabolized via CYP3A4 [44–51]. We
assumed dose linearity since recent reports have demon-
strated that buprenorphine shows a linear increase in the
exposure across a wide dose range from 0.060 to 12 mg
[52, 53].
We acknowledge that our study has limitations which in-
clude that it was designed mainly to evaluate the pharmaco-
kinetics of buprenorphine. For this goal, we normalized the
pharmacokinetic values to an oral buprenorphine dose of
1 mg. This made doze normalization challenging in
pharmacodynamical calculations and in estimating subjective
adverse effects. However, dose normalization cannot be used
for pharmacodynamical results and subjective adverse effects.
We drew blood samples for 18 h, and longer sampling time
might have increased the reliability in the pharmacokinetic
calculations, especially in determining the elimination half-
life. Therefore, the values of elimination half-life and renal
clearance should be interpreted with these limitations in mind.
The strengths of our study were the two-phase cross-over
design and the controlled conditions that confirmed the com-
pliance to blood sampling and urine collection. Using current
study design, we could also avoid a possible pharmacokinetic
interference caused by naloxone on the interaction between
buprenorphine and voriconazole.
In conclusion, our results show that clinically used doses of
voriconazole greatly increase the exposure to oral
buprenorphine. Although oral buprenorphine is not common-
ly used in clinical settings, strong inhibition of its first-pass
metabolism should be taken into account also when
voriconazole or other potent CYP3A4 inhibitors are pre-
scribed to patients receiving sublingual buprenorphine.
Patients should be well informed and familiarized with sub-
lingual dosing, as some part of the dose is easily ingested and
swallowed. Further studies are warranted on the effect of
transporter inhibitors on norbuprenorphine pharmacokinetics
and pharmacodynamics because its high concentrations could
increase buprenorphine toxicity.
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